aTyr Pharma, Inc. (NASDAQ:LIFE) Expected to Announce Quarterly Sales of $130,000.00

Equities analysts forecast that aTyr Pharma, Inc. (NASDAQ:LIFE) will announce sales of $130,000.00 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for aTyr Pharma’s earnings, with the highest sales estimate coming in at $150,000.00 and the lowest estimate coming in at $80,000.00. aTyr Pharma reported sales of $140,000.00 during the same quarter last year, which indicates a negative year-over-year growth rate of 7.1%. The firm is scheduled to announce its next quarterly earnings report on Thursday, March 25th.

According to Zacks, analysts expect that aTyr Pharma will report full-year sales of $8.53 million for the current fiscal year, with estimates ranging from $8.50 million to $8.55 million. For the next financial year, analysts expect that the company will post sales of $14.57 million, with estimates ranging from $300,000.00 to $28.85 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow aTyr Pharma.

aTyr Pharma (NASDAQ:LIFE) last released its quarterly earnings results on Tuesday, November 17th. The biotechnology company reported ($0.68) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.74) by $0.06. aTyr Pharma had a negative return on equity of 52.75% and a negative net margin of 202.02%. The business had revenue of $0.15 million for the quarter, compared to analysts’ expectations of $0.16 million.

LIFE has been the topic of several research reports. Oppenheimer restated a “buy” rating on shares of aTyr Pharma in a research note on Tuesday, September 22nd. Zacks Investment Research cut aTyr Pharma from a “hold” rating to a “sell” rating in a research note on Wednesday, November 18th. Finally, ValuEngine upgraded aTyr Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, September 1st. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $10.19.

NASDAQ LIFE traded down $0.19 on Tuesday, hitting $4.09. 197,293 shares of the stock traded hands, compared to its average volume of 304,306. The stock has a 50-day moving average of $3.91 and a 200 day moving average of $3.89. aTyr Pharma has a twelve month low of $2.13 and a twelve month high of $7.62. The company has a market capitalization of $41.66 million, a P/E ratio of -1.54 and a beta of 2.14.

Large investors have recently bought and sold shares of the company. Ardsley Advisory Partners LP bought a new position in aTyr Pharma in the 3rd quarter worth approximately $65,000. BlackRock Inc. increased its position in aTyr Pharma by 23.8% during the third quarter. BlackRock Inc. now owns 41,411 shares of the biotechnology company’s stock worth $134,000 after buying an additional 7,948 shares during the last quarter. Acadian Asset Management LLC grew its position in shares of aTyr Pharma by 22.2% in the third quarter. Acadian Asset Management LLC now owns 83,052 shares of the biotechnology company’s stock valued at $269,000 after purchasing an additional 15,088 shares during the last quarter. Finally, Two Sigma Advisers LP lifted its stake in shares of aTyr Pharma by 122.7% in the second quarter. Two Sigma Advisers LP now owns 80,950 shares of the biotechnology company’s stock valued at $359,000 after buying an additional 44,600 shares during the period. 56.03% of the stock is owned by institutional investors.

aTyr Pharma Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial.

See Also: What is the definition of a trade war?

Get a free copy of the Zacks research report on aTyr Pharma (LIFE)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with's FREE daily email newsletter.